Skip to main content

Advertisement

Table 1 Basic information on the 5 clinical trials included in this meta-analysis

From: Differences between children and adolescents in treatment response to atomoxetine and the correlation between health-related quality of life and Attention Deficit/Hyperactivity Disorder core symptoms: Meta-analysis of five atomoxetine trials

Study Sample size (n) Design Duration Dose mg/kg/day Procedure
Study 1 (S) Svanborg et al, 2009 [36] 99 Randomized, double-blind, placebo-controlled 10 weeks 1.2 Diagnosis based on ADHD-RS, confirmed with KSADS, stimulant-naïve patients No ongoing psychotropic medication or structured PT
Study 2 (E) Escobar et al, 2009 [37] 149 Randomized, double-blind, placebo-controlled 12 weeks 1.2 Diagnosis based on ADHD-RS, confirmed with KSADS stimulant-naïve patients No ongoing psychotropic medication or structured PT CGI≥4 at inclusion
Study 3 (I) Dell'Agnello et al, 2007 [38] 139 Randomized, double-blind, placebo-controlled 8 weeks 1.2 Diagnosis based on ADHD-RS, confirmed with KSADS, ADHD+ODD patients No ongoing psychotropic medication or structured PT CGI≥4 at inclusion
Study 4 (UK) Prasad et al, 2007 [23] 201 Open-label, atomoxetine vs standard of care 10 weeks 0.5-1.8 Diagnosis based on ADHD-RS, confirmed with KSADS No ongoing psychotropic medication or structured PT
Study 5 (CAN) Dickson et al, 2007 [39] 206 Open-label, atomoxetine only 12 weeks 0.5-1.4 Diagnosis based on ADHD-RS, confirmed with KSADS
  1. Abbreviations: ADHD-RS, Attention Deficit/Hyperactivity Disorder Rating Scale; KSADS, Kiddie Schedule for Affective Disorders and Schizophrenia for School Age Children; PT, psychotherapy; CGI, Clinical Global Impression; ODD, oppositional defiant disorder; S, Sweden; E, Spain; I, Italy; UK, United Kingdom; CAN, Canada